Trial Profile
A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Selinexor (Primary)
- Indications CNS cancer; Glioma; Lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 28 Sep 2023 Planned End Date changed from 4 Oct 2023 to 22 Sep 2024.
- 07 Oct 2022 Planned End Date changed from 30 Sep 2022 to 4 Oct 2023.
- 07 Apr 2022 Planned primary completion date changed from 31 Mar 2022 to 30 Sep 2022.